Topics covered: Reimbursement Trends, Orphan Drugs, Oncology Drug Development, FDA Approval Process, Biotechnology and Pharmaceutical Valuations
Companies covered: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), PDL BioPharma, Inc. (NASDAQ:PDLI), Celgene Corporation (NASDAQ:CELG), Biogen Inc. (NASDAQ:BIIB), Amgen Inc. (NASDAQ:AMGN), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Seattle Genetics, Inc. (NASDAQ:SGEN), Pfizer, Inc. (NYSE:PFE), Pharmacyclics, Inc. (NASDAQ:PCYC), Merck & Company, Inc. (NYSE:MRK), Incyte Corporation (NASDAQ:INCY), Idenix Pharmaceuticals Inc., Gilead Sciences, Inc. (NASDAQ:GILD), Bristol-Myers Squibb Company (NYSE:BMY), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Pluristem Therapeutics, Inc. (NASDAQ:PSTI), ImmunoGen, Inc. (NASDAQ:IMGN), Curis, Inc. (NASDAQ:CRIS), ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), United Therapeutics Corporation (NASDAQ:UTHR), Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Onyx Pharmaceuticals Inc., Isis Pharmaceuticals, Inc. (NASDAQ:ISIS)
